Beyond Depth: A Phenotypic Classification of Adenomyosis — Edematous vs. Fibrotic

For over a century, adenomyosis was categorized primarily by its depth of invasion into the uterine wall. However, modern clinical observation and molecular research suggest that this “depth-based” model fails to capture the true nature of the disease. A more functional classification—categorizing adenomyosis into Edematous (Congestive) and Fibrotic (Sclerotic) phenotypes—provides a clearer map for understanding patient symptoms, systemic impacts, and surgical outcomes.

This article explores these two phenotypes through the lens of pathophysiology, systemic immune signaling, and the biomechanics of tissue repair.

1. The Edematous Phenotype: The Inflammatory “Pump”

The edematous phenotype is characterized by a “boggy,” globally enlarged uterus with high water content and intense vascularization. This is not merely a localized swelling; it is a source of chronic biochemical stress.

Systemic Inflammation and Vascular Seepage

The uterus is one of the most highly vascularized organs in the body. In edematous adenomyosis, the ectopic endometrial glands behave like “permanent wounds.” This triggers a massive recruitment of inflammatory cytokines, including Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-$\alpha$), and Prostaglandins ($PGE_2$).

During menstruation, as these ectopic glands bleed into the myometrium, the inflammatory response peaks. Because of the uterus’s rich blood supply, these mediators are not contained. Instead, they are “pumped” into the systemic circulation. This “cytokine spillage” explains why patients often report systemic symptoms—such as chronic fatigue, brain fog, and joint pain—that mirror systemic inflammatory response syndromes.

Imaging and Clinical Profile

• Ultrasound/MRI: Manifests as diffuse thickening of the Junctional Zone (JZ) with high signal intensity on T2-weighted MRI, reflecting high fluid and blood content.

• Primary Symptom: Heavy Menstrual Bleeding (Menorrhagia). The “boggy” muscle cannot contract effectively to constrict spiral arteries, leading to significant blood loss.

2. The Fibrotic Phenotype: Pathological Healing & Genetic Predisposition

The fibrotic phenotype represents a transition from inflammation to chronic structural remodeling. In this type, the hallmark is the proliferation of dense connective tissue and smooth muscle.

The “Hyper-Fibrotic” Responder

Not every patient with adenomyosis develops significant fibrosis. Research suggests a genetic and molecular predisposition where the “Tissue Injury and Repair” (TIAR) mechanism is stuck in an overactive loop. Driven by pathways like TGF-$\beta$/Smad3, certain individuals are more prone to Epithelial-Mesenchymal Transition (EMT)—a process where epithelial cells transform into migratory, collagen-producing myofibroblasts.

Mechanical Failure and Pain

In the fibrotic phenotype, the soft, compliant muscle of the uterus is replaced by rigid, plastic-like scar tissue. This creates a “mechanical mismatch.” When the uterus tries to contract during a period, these hardened, sclerotic zones cannot move. The resulting high-pressure zones within the uterine wall cause the intense, sharp, labor-like pain characteristic of this phenotype.

Imaging and Clinical Profile

• Ultrasound/MRI: Appears as localized, dark, low-signal areas (adenomyomas). The tissue is dense and resists compression.

• Primary Symptom: Severe Pain (Dysmenorrhea). The lack of tissue compliance during contractions is the primary driver of patient agony.

Comparative Analysis: Edematous vs. Fibrotic

Clinical Implications: Phenotype-Driven Care

Understanding whether a patient is predominantly edematous or fibrotic changes the treatment algorithm.

• Edematous Management: Strategies often focus on “cooling the fire” with hormonal suppression and anti-inflammatories. However, this phenotype is also highly responsive to Microwave Ablation (MWA). By applying thermal energy, MWA can effectively coagulate the highly vascularized ectopic tissue, significantly reducing the “inflammatory pump” effect and controlling heavy bleeding.

• Fibrotic Management: Because you cannot “un-scar” a uterus with medication, this phenotype generally requires structural intervention. Microwave Ablation is a primary tool here, as it can target and “soften” dense adenomyotic lesions. However, in cases of extensive, rigid scarring, targeted surgical excision may be necessary to restore uterine compliance and alleviate pain.

References (Verified PubMed/PMC)

• Liu X, et al. (2016). Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis. PubMed

• Zhou S, et al. (2021). $\beta$-catenin activates TGF-$\beta$-induced epithelial–mesenchymal transition in adenomyosis. PMC

• Vannuccini S, Petraglia F. (2019). Recent advances in understanding and managing adenomyosis. PMC

• Lin J, et al. (2022). Ultrasound-guided microwave ablation for symptomatic adenomyosis. PMC

• Bourdon M, et al. (2021). Immunological changes associated with adenomyosis: a systematic review. PubMed